asa guidelines semaglutide Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement ASA: Hold GLP-1 Agonists Before

Weight loss without exercise is possible on semaglutide, but the composition of that weight loss changes dramatically

Retrieved from Heinitz, S., Hollstein, T., Ando, T., et al

Rather than daily injections, the protocol requires a heavier 2.5 mg systemic dose injected twice per week

You can also stay on a lower dose for longer if you need to. You may notice a reduced appetite or that you arent feeling as hungry between meals or craving food as much as before

For patients without established atherosclerotic CV disease (ASCVD) or chronic kidney disease (CKD) and for whom there is a compelling need to minimize weight gain or promote weight loss, the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) guidelines recommend GLP-1RA and sodium-glucose co-transporter-2 inhibitor (SGLT2i) drugs as the preferred second-line treatment option for patients with inadequate glycemic control despite use of metformin [1, 9]